tbuckley/cabot-search huggingface dataset:
Smoking Cessation and the Risk for Type 2 Diabetes Mellitus
Authors: Hsin-Chieh Yeh
Journal: Annals of Internal Medicine (2010)

Letters1 June 2010Smoking Cessation and the Risk for Type 2 Diabetes MellitusHsin-Chieh Yeh, PhD and Frederick L. Brancati, MD, MHSHsin-Chieh Yeh, PhDFrom Johns Hopkins University, Baltimore, MD 21205.Search for more papers by this author and Frederick L. Brancati, MD, MHSFrom Johns Hopkins University, Baltimore, MD 21205.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-152-11-201006010-00021 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:We agree with Dr. Ziegelstein that smoking cessation may trigger depression, which could in turn increase the risk for type 2 diabetes because of unhealthy behaviors, decreased insulin sensitivity, or increased systemic inflammation. Unfortunately, the ARIC study did not include a specific assessment for depression. At the 3-year follow-up visit, ARIC participants were asked to complete a survey of vital exhaustion (1) to measure feelings of fatigue and exhaustion that might precede myocardial infarction. As Dr. Ziegelstein suspected, vital exhaustion was greater in quitters than in never-smokers (mean score adjusted for age, sex, race, and ARIC center, 11.3 ...Reference1. Appels A, Höppener P, Mulder P. A questionnaire to assess premonitory symptoms of myocardial infarction. Int J Cardiol. 1987;17:15-24. [PMID: 3666994] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Hsin-Chieh Yeh, PhD; Frederick L. Brancati, MD, MHSAffiliations: From Johns Hopkins University, Baltimore, MD 21205.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoSmoking, Smoking Cessation, and Risk for Type 2 Diabetes Mellitus Hsin-Chieh Yeh , Bruce B. Duncan , Maria Inês Schmidt , Nae-Yuh Wang , and Frederick L. Brancati Smoking Cessation and the Risk for Type 2 Diabetes Mellitus Roy C. Ziegelstein Smoking Cessation and the Risk for Type 2 Diabetes Mellitus Altan Onat Smoking Cessation and the Risk for Type 2 Diabetes Mellitus Richard L. Shriner , Noni A. Graham , and Mark S. Gold Metrics Cited byEarly to Midlife Smoking Trajectories and Cognitive Function in Middle-Aged US Adults: the CARDIA Study 1 June 2010Volume 152, Issue 11Page: 755-756KeywordsBody mass indexEating habitsMyocardial infarctionQuestionnairesSmoking habitsType 2 diabetesWeight gainWeight loss ePublished: 1 June 2010 Issue Published: 1 June 2010 Copyright & PermissionsCopyright © 2010 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
LOCALIZED INFECTIOUS DISEASES AS A SEQUENCE OF SLIGHT INJURIES.
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
BRITISH MEDICAL BENEVOLENT FUND
Authors: An Iifljjrolecd, Colotomiiy Tube, C Duncan, F Fitzwilliams
Journal: BMJ (1912)

The paramount importance of evacuating the septic and highly toxic contents of the bowel with the least possible delay in cases of acute obstruction has long been recognized; unfortunately this is not always an easy matter, ancd after fixing the ordinary colotomy tuibe of Paul's pattern into the gut our attempts to empty the bowel are confined to giving aperients by the mouth, and more recently the administration of eserine subcutaneously to stimulate peristalsis.As, however, vomiting may continue for soome hours, or even days, after the operation, aperients
Familial prevalence of gallstones in first-degree relatives of patients with gallstones
Authors: Y Romero
Journal: Hepatology (1996)

Familial Prevalence of Gallstones in First-Degree Relatives of Patients With Gallstones patients should always be screened for gallstone occur-To the Editor: rence.''Why?The most likely consequence is that their asymptomatic gallstones will be removed, exposing We write in response to the recent article by Shiv et them to immediate postsurgical complications, late al., ''High Familial Prevalence of Gallstones in the postcholecystectomy diarrhea, or gastroduodenal re-First-Degree Relatives of Gallstone Patients.'' 1 Flaws flux.The authors themselves state that of the ''eleven in the study design may have easily biased the results, of . . .51 (21.6%) relatives'' who ''had symptoms of leading to costly recommendations without adequate upper abdominal discomfort and dyspepsia . . .these evidence.symptoms were not characteristic of gallstone disease.''With regard to study design, a high degree of selec-We find the endorsement of expensive and possibly deltion bias was present from the outset.For example, eterious recommendations frightening, especially only subjects with gallstones who had two living firstwhen based on the results of a single study.degree relatives willing to participate in the study were To be clear, we are not dismissing the possibility that included.It is easy to conceive that subjects whose famcertain families are at higher risk for the development of ily members did not welcome a familial trend toward cholelithiasis.However, this study, because of design ercholelithiasis had negative personal interests in the rors, cannot be relied upon to provide the correct answer.project and would be less likely to enroll (or vice versa).In addition, which first-degree family members partici-YVONNE ROMERO, M.D. pated was also a nonrandom, self-selection process.Gastroenterology Fellow Overall, the study design favors enrollment of family members with gastrointestinal symptoms or those SIDNEY F. PHILLIPS, M.D. members who were curious to their gallstone status.
Geriatric Medicine
Authors: Eric B. Larson
Journal: JAMA (1991)

As physicians find themselves spending more time caring for older patients, American medicine has developed an increased appreciation of some of the important features of geriatric medicine. Medical problems of aging are less likely to be just "medical" and short-term. Rather, the conscientious physician practicing good geriatric medicine appreciates the social, environmental, economic, and ethical dimensions that are part of the patient's medical problems. The time horizon for most diseases of old age, their amelioration or prevention, is long-term. Advance planning and the availability of effective caregivers in a supportive environment have important effects on patient well-being. As physicians have added the geriatric medicine perspective to their practice style, the knowledge base of geriatric medicine has also advanced. Advances have occurred from careful, painstaking, time-consuming clinical research on common chronic diseases, discoveries in clinical and basic science laboratories, and evaluation of programs designed to promote well-being (for example, "successful aging")
Environmental Medicine
Authors: Ronald E. Gots
Journal: JAMA (1996)

<i>Environmental Medicine</i>was an extraordinarily difficult book to compile, and the editors and authors carried out the task as well as could be done. If this sounds like mute praise, it is, because it is tempered by quandaries: what exactly is environmental medicine and will this nearly 800-page tome provide a valuable adjunct to a medical library? Environmental medicine is everything not hereditary. Infectious diseases, allergies, and disorders caused by radiation, heat, pesticides, chemicals, even vibration all fall within this medical designation and the landscape of this book. Well-known and generally understood clinical phenomena, such as allergy, poisoning, and heatstroke, are addressed. Low-level chemical exposures and their effects on various organ systems (what many think of as "environmental medicine") are intertwined mostly as unknowns, animal studies, or suspicions. The very breadth of environmental medicine makes the field an odd admixture of well-established disorders, worries of the day, and abject speculation.
Sleep patterns scrutinized as depression therapy
Authors: C. A. Raymond
Journal: JAMA (1988)

EARLY TO BED, early to rise, may be the new prescription for depression. Twenty-two years ago, quite by chance, psychiatrists discovered that a night without sleep sometimes cured depression. Since then, more than 1000 patients have been subjected to total sleep deprivation; 70% of those with bipolar depression and 60% of those with unipolar depression respond to the treatment (<i>Prog Neuropsychopharmacol Biol Psychiatry</i>1983;7:351-364). While the effect is immediate (unlike that of antidepressant drugs), it is also short-lived. Relapse typically occurs following a night of recovery sleep. But evidence is accumulating to suggest that partial sleep deprivation—if it occurs at the right time of the night— can exert an effective and lasting benefit to depressed persons (<i>Arch Gen Psychiatry</i>1980;37:267-271). This may open the way for a simple and far more tolerable therapy, even in those patients who do not respond to drugs, and narrow the search for the mechanisms
Books Received
Journal: JAMA (1983)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Errata
Journal: BMJ (1843)

It was considered proper to apprise the husband and sister of the patient of her present desperate con-4ion, and to inform them that the oinly probable though sligitt chance of escape rested either on the operation of gastrotomy being performed, should tlle patient rally, or on leavinig the case to the healing powers of nature.The relations immediately decided that no operation should be performed.Although I thoroughly disagree with Dr. Denman in the following sentence, as a general rutle, still,
A System of Practical Medicine by American Authors.
Journal: JAMA (1897)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Effects of dietary manipulation on vascular status of patients with peripheral vascular disease
Authors: K. Hutchinson
Journal: JAMA (1983)

In a one-year, double-blind clinical trial, 45 patients with peripheral vascular disease (PVD) were randomly assigned to either the American Heart Association Hyperlipidemia Diet C (n=20) or a low-fat, high-fiber, complex carbohydrate diet similar to the Pritikin Maintenance Diet (n=25). Vascular status and blood lipid levels were monitored at 0, 2, 4, 6, and 12 months. Walking distance increased significantly in both groups, with no difference between groups. No vascular parameters changed significantly, suggesting that increased walking distance was due to improved metabolic capacity of the muscle. A trend toward lower blood lipid values was observed, with no significant differences within or between groups. We conclude that while patients with PVD benefit from a program of diet and exercise, there is no apparent advantage to the more difficult complex carbohydrate diet. (<i>JAMA</i>1983;249:3326-3330)
Lost in the system: identification of patients with undiagnosed primary biliary cholangitis
Authors: Jorge Yebra Carmona, Carla Amaral, Esther Molina, Maria Hernández Pérez, Carolina Suarez Cabredo, Isabel Spigarelli de Rábago, Cristina Julia Suárez Ferrer, Dalia Morales Arraez, Felicitas Diaz-Flores, Javier Fernandez, Pablo Eiras, Manuel Hernández Guerra, Antonio Olveira Martin
Journal: Journal of Hepatology (2020)
In Reply
Authors: Rogerio C. Lilenbaum, Mark Socinski
Journal: Journal of Clinical Oncology (2007)

We appreciate the opportunity to comment on the work discussed in the letter by Gradilone and colleagues.Their contention that increased expression of multidrug resistance-associated protein 4 induced by celecoxib may compromise the efficacy of irinotecan, but not other chemotherapeutic agents, in non-small-cell lung cancer (NSCLC) is provocative and merits further research.It adds to an already large body of literature that attempts to provide a scientific basis for the use of cyclooxygenase (COX)-2 inhibitors in the treatment of NSCLC, yet to be proven in the clinical arena.A few comments and clarifications about our study. 1Firstly, the trial did not have sufficient power to address survival.A trend toward a detriment in survival was indeed observed for patients treated with celecoxib and chemotherapy, but it did not reach statistical significance and should not be interpreted as definitive.Nonetheless, the statement that our results were "strongly conflicting with other clinical studies" is incorrect, since no clinical trial has yet conclusively shown a positive impact of celecoxib in the treatment of NSCLC patients.Secondly, and regrettably, our trial did not include a correlative science component.At the time it was designed, it addressed a rapidly growing sentiment among oncologists that celecoxib was potentially useful in the treatment of NSCLC patients.Our results showed that, at least in unselected patients with advanced disease, the use of celecoxib in combination with chemotherapy was of no benefit.Essentially, our trial sent a cautionary message against the use of celecoxib without more carefully predefined criteria, akin to the combination of tyrosine kinase inhibitors with chemotherapy in advanced NSCLC.However, our trial did not exclude the possibility that in selected patients, such as those with overexpression of COX-2, or other molecular features yet to be defined, celecoxib might have a positive impact.Clearly, as indicated at the end of our article, additional work is warranted.
WAR GASES AND CHEMICAL WARFARE
Journal: JAMA (1918)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Wrong Figures Cited
Journal: JAMA (1972)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ACTR-11. PHASE II STUDY OF SINGLE AGENT BUPARLISIB IN RECURRENT/REFRACTORY PRIMARY (PCNSL) AND SECONDARY CNS LYMPHOMA (SCNSL)
Authors: Christian Grommes, Elena Pentsova
Journal: Neuro-Oncology (2016)

PCNSL is an aggressive primary brain tumor. Outcome and treatment options are poor for recurrent/refractory (r/r) patients with response rates between 30–60% and progression free survival (PFS) of 2–6 months. PI3K inhibition has shown promising response in some B-cell malignancies. This phase II trial investigates Buparlisib in patients with r/r PCNSL and SCNSL. Eligible patients had r/r PCNSL/SCNSL, age≥18, KPS≥50, normal end-organ function, unrestricted number of prior therapies. Systemic disease needed to be absent in SCNSL patients. Patients received Buparlisib 100mg daily. The trial was closed prematurely due to limited clinical response. Four patients were enrolled: age 55, 60, 68, 79 with KPS of 90, 100, 90, 60, respectively. Three were men; 50% had PCNSL. All had parenchymal disease. Median prior CNS directed treatment was 2 (range 1–3); all methotrexate regimens. Two grade 4 toxicities (lymphopenia, neutropenia) were observed that resolved after drug was held. Most common toxicities were hyperglycemia, thrombocytopenia, and lymphopenia. Overall response rate was 25% with one partial response. This patient developed psychiatric symptoms within 8 weeks of treatment and drug was discontinued. Three patients developed neurologic symptoms at a median of 37 days after trial drug initiation all due to disease progression. Median progression free survival was 39 days. Median overall survival was 196 days. Buparlisib concentrations were assessed 2h after drug treatment on day 15 in plasma and CSF. Mean plasma concentration was 1104ng/ml (range: 844–1610); mean CSF concentration 139.5ng/ml (82.9–205). CSF concentration in the trial population (medium: 340nM; range: 202–499) was below the IC50 observed to induce cell death in lymphoma cells in vitro(>500nM). CD79B mutations were found in 3/4 patients. Patients with CNS lymphoma tolerate drug with acceptable toxicities. Treatment did not result in clinical response possibly due to CNS concentration below a meaningful IC50. Additionally, Buparlisib might not have single agent activity.
Histamine content of rectal mucosa in ulcerative colitis
Journal: Gut (1967)

Colo-rectal anastomosis with a suturing apparatus in resection of the rectum and colon 191 apparatus can be introduced through the anus and through the lumen of the sigmoid colon and ileum from the abdominal cavity.All these patients feel well.They defaecate two to four times a day as before the operation.On radiological examination after operation motor function was normal and narrowing of the anastomosis was not observed (Fig. 4).With the help of this apparatus anastomosis in the depth of the pelvic cavity becomes easier, and the intestinal wall can be divided much lower than the cancer, thus extending the indications for resection of the rectum but preserving the sphincter.The duration of the operation is shorter and it causes less trauma. CONCLUSIONSWith apparatus KC-28 colo-rectal and ileorectal anastomoses can be made successfully.This apparatus shortens low anterior resection of the rectum by 20 to 25 minutes.With the apparatus the operation can be used when the tumour is 7 cm.from the anus in women and 8 to 9 cm. in men.
"DOCTORS, DOLLARS AND DISEASE"—RADIO EDUCATION OR PROPAGANDA
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal